Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.
![](/sites/default/files/styles/hero/public/2017-12/amicus%20brief%20-%20stock.jpg?h=397da195&itok=6wR3BiXA)
![](/sites/default/files/styles/hero_tablet/public/2017-12/amicus%20brief%20-%20stock.jpg?h=397da195&itok=9P2Wn0zz)
![](/sites/default/files/styles/hero_mobile/public/2017-12/amicus%20brief%20-%20stock.jpg?h=397da195&itok=WMrlNKGw)
Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.